arrow
J

John D. Graham

royal marsden nhs foundation trust
H指数:60
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
2022-06-017
OAAI
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)

大分割放疗对前列腺癌患者报告结果的影响: CHHiP试验 (CRUK/06/016) 中长达5年的结果

2021-12-0119
OA
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received
2020-03-01116
OAAI
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
2018-12-0119
OAAI
National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting
2018-06-05116
OAAI
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial

常规和大分割大剂量放疗对老年前列腺癌的疗效和安全性: CHHiP试验的亚组分析

2018-04-0132
OAAI
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

多西他赛、唑来膦酸或两者联合用于前列腺癌一线长期激素治疗 (STAMPEDE): 一项适应性、多臂、多阶段、平台随机对照试验的生存结果

LANCET
IF88.5
2016-03-011.6K
OAAI